DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Pf-04531083 is an investigational drug.
There have been 6 clinical trials for Pf-04531083. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2011.
The most common disease conditions in clinical trials are Chronic Pain, Toothache, and [disabled in preview]. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are twenty-four US patents protecting this investigational drug and two hundred and seventy-eight international patents.
Recent Clinical Trials for Pf-04531083
|Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain||Pfizer||Phase 2|
|Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin||Pfizer||Phase 1|
|A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.||Pfizer||Phase 1|
Top disease conditions for Pf-04531083
Top clinical trial sponsors for Pf-04531083
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pf-04531083||Start Trial||Substituted pyridazines for the treatment of pain||INHIBITAXIN LIMITED (Sandwich Kent, GB)||Start Trial|
|Pf-04531083||Start Trial||Prodrugs of pyridone amides useful as modulators of sodium channels||VERTEX PHARMACEUTICALS INCORPORATED (Boston, MA)||Start Trial|
|Pf-04531083||Start Trial||Pyridine derivatives||Pfizer Inc. (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|